Windtree Therapeutics, Inc. Share Based Compensation of Revenue

Share Based Compensation of Revenue of WINT for past 10 years: annual, quarterly and twelve month trailing (TTM) including Share Based Compensation of Revenue growth rates and interactive chart.


Highlights and Quick Summary

  • Share Based Compensation of Revenue for the quarter ending June 29, 2020 was 0.0% (a NaN% decrease compared to previous quarter)
  • Year-over-year quarterly Share Based Compensation of Revenue decreased by NaN%
  • Annual Share Based Compensation of Revenue for 2019 was 3394.44% (a 6255.44% increase from previous year)
  • Annual Share Based Compensation of Revenue for 2018 was 53.41% (a -52.08% decrease from previous year)
  • Annual Share Based Compensation of Revenue for 2017 was 111.45% (a 35.06% increase from previous year)
  • Twelve month Share Based Compensation of Revenue ending June 29, 2020 was 0.0% (a NaN% decrease compared to previous quarter)
  • Twelve month trailing Share Based Compensation of Revenue decreased by NaN% year-over-year
Trailing Share Based Compensation of Revenue for the last four month:
29 Jun '20 30 Mar '20 30 Dec '19 29 Sep '19
0.0% 0.0% 1338.84% 0.0%
Visit stockrow.com/WINT for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Share Based Compensation of Revenue of Windtree Therapeutics, Inc.

Most recent Share Based Compensation of Revenueof WINT including historical data for past 10 years.

Interactive Chart of Share Based Compensation of Revenue of Windtree Therapeutics, Inc.

Windtree Therapeutics, Inc. Share Based Compensation of Revenue for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 0.0% 0.0%
2019 0.0% 0.0% 1100.63% 3825.0% 3394.44%
2018 82.89% 63.32% 13.32% 204.9% 53.41%
2017 800.0% 4935.29% 0.0% 168.95% 111.45%
2016 42.67% 34.34% 295.28% 877.33% 82.52%
2015 0.0% 790.91% 581.33% 414.66% 0.0%
2014 73.48% 204.55% 93.41% 3077.42% 138.38%
2013 1174.32% 1463.33% 481.87% 850.0% 834.02%
2012 0.0% 0.0% 0.0% 0.0% 1676.92%
2011 0.0% 0.0% 140.8% 82.94% 234.36%
2010 0.0% 0.0% 0.0% 0.0% 0.0%

Business Profile of Windtree Therapeutics, Inc.

Sector: Medical
Industry: Drugs
Windtree Therapeutics, Inc., a biotechnology and medical device company, engages in the research and development of products that focus on acute pulmonary and cardiovascular diseases. Its four lead development programs include istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as in Phase 2a clinical trial for the treatment of early cardiogenic shock; AEROSURF, an aerosolized KL4 surfactant, which is in Phase 2b clinical trial to treat respiratory distress syndrome (RDS) in premature infants; lyophilized KL4 surfactant for the treatment of lung injury resulting from COVID-19; and Rostafuroxin that is in Phase 2b clinical trial for the treatment of genetically associated hypertension. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. Windtree Therapeutics, Inc. was incorporated in 1992 and is headquartered in Warrington, Pennsylvania.